Objective:
To analyze the real-world use of avacincaptad pegol in conjunction with anti-VEGF therapy for patients with geographic atrophy.
Approach:
- Study Design: Analysis of IRIS Registry data involving 10,181 patients aged 50 years or older with geographic atrophy who received their first avacincaptad pegol injection between September 1, 2023, and August 31, 2024.
Key Findings:
- 34.3% of patients had neovascular age-related macular degeneration (nAMD) and 28.2% had choroidal neovascularization (CNV) at baseline.
- Mean intervals between avacincaptad pegol injections were 7.2 weeks for eyes receiving anti-VEGF and 6.9 weeks for those not receiving it.
Interpretation:
Concomitant anti-VEGF therapy did not meaningfully affect avacincaptad pegol treatment patterns and was associated with an expected safety profile.
Limitations:
- The study was limited to a specific cohort from the IRIS Registry.
- Data on long-term outcomes and broader patient demographics were not provided.
Conclusion:
Concomitant anti-VEGF therapy showed similar treatment patterns and safety profiles for avacincaptad pegol in this real-world setting.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.